• Ingrida Platais, Tamar Tsereteli, Galina Grebennikova, Tatyana Lotarevich, and Beverly Winikoff.
• Gynuity Health Projects, New York, NY, USA. Electronic address: iplatais@gynuity.org.
• Int J Gynaecol Obstet. 2016 Sep 1; 134 (3): 268-71.

ObjectiveTo evaluate the efficacy of at-home medical abortion in Kazakhstan.MethodsA comparative, non-randomized study was undertaken at three clinics in Kazakhstan between October 10, 2013, and November 27, 2014. Women who sought medical abortion and had an intrauterine pregnancy of up to 70days were enrolled. All participants took 200mg mifepristone followed by 600μg sublingual misoprostol 24-48hours later. Women were offered the choice to take mifepristone at the clinic or at home; all took misoprostol at home. Abortion completion was assessed at an in-clinic follow-up appointment scheduled for all participants 2weeks after mifepristone administration.ResultsOf 290 enrolled women, 185 (63.8%) chose to self-administer mifepristone at home. Three (1.0%) of 289 women included in outcome analyses required surgical intervention for incomplete abortion. Therefore, the overall success rate was 99.0% (95% confidence interval 97.0%-99.7%). No serious adverse events occurred.ConclusionOutpatient medical abortion with mifepristone and misoprostol is safe and effective up to 70days of pregnancy. This service should be offered to women in Kazakhstan. ClinicalTrials.gov: NCT02018796.Copyright © 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

29 keywords...

hide…